Invention Grant
- Patent Title: Nicotinamide RIPK1 inhibitors
-
Application No.: US17882709Application Date: 2022-08-08
-
Publication No.: US11767310B2Publication Date: 2023-09-26
- Inventor: Kevin Patrick Cusack , Michael Zeller Hoemann , David Andrew Kinsman , Sami Osman , James Patrick Stambuli , Maria Anastasia Argiriadi , Ciaran O'Reilly , Hannah Dexter , Euan Fordyce , Steve St. Gallay
- Applicant: AbbVie Inc.
- Applicant Address: US IL North Chicago
- Assignee: AbbVie Inc.
- Current Assignee: AbbVie Inc.
- Current Assignee Address: US IL North Chicago
- Agency: Foley Hoag LLP
- Agent Hathaway P. Russell; Laura A. Wzorek
- Main IPC: C07D401/06
- IPC: C07D401/06 ; A61P1/04 ; C07D405/14 ; C07D413/06 ; C07D417/06 ; C07D498/04
Abstract:
Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. Also provided are methods of treating Ulcerative Colitis using a compound of Formula (I).
Public/Granted literature
- US20230127127A1 NICOTINAMIDE RIPK1 INHIBITORS Public/Granted day:2023-04-27
Information query
